Michael S. Ip, MD
Michael S. Ip, MD, is Professor, Department of Ophthalmology at the David Geffen School of Medicine at the University of California - Los Angeles. He is a member of the Doheny Eye Institute and currently serves as the Medical Director of the Doheny Image Reading Center. Prior to June 2016, Dr. Ip was on faculty at the University of Wisconsin School of Medicine and Public Health in Madison, WI and was a co-director of the Fundus Photograph Reading Center at the University of Wisconsin. He also served as Director of the Retina Service at the William S. Middleton Memorial Veterans Hospital in Madison, WI. Dr. Ip received his medical degree from New York University and completed his internship at Lenox Hill Hospital, both in New York, New York. He completed his residency at the University of Pittsburgh School of Medicine in Pennsylvania followed by a fellowship in vitreoretinal surgery at the New England Eye Center, Tufts University, in Boston, Massachusetts.
Dr. Ip’s research focuses on the design and conduct of clinical trials investigating treatments for diabetic retinopathy, AMD, and retinal venous occlusive disease. Previously as Co-Director of the Fundus Photograph Reading Center, he has assisted with the collection, analysis, and dissemination of important secondary outcomes in numerous industry and NIH-funded ophthalmic clinical trials. As a clinical site investigator, he has served as the Principal Investigator on over 17 clinical trials. He has also served as the protocol chair for the clinical trial conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema and as the National Principal Investigator for the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study. In 2003, Dr. Ip and colleagues received an award from the NEI to conduct the SCORE Study. In 2013, this group received funding from the NEI to conduct the SCORE2 Study. This avenue of research continues in his role as the Medical Director of the Doheny Image Reading Center.
He has authored more than 120 peer-reviewed articles, 25 book chapters, and more than 70 abstracts on these topics as well as has given many national and international presentations. Dr. Ip is also a reviewer for the following six journals: Ophthalmic Surgery and Lasers, Investigative Ophthalmology and Visual Science, American Journal of Ophthalmology, Retina, and Ophthalmology. He is as well a former Associate Editor for Archives of Ophthalmology. Furthermore, Dr. Ip has been recognized with several honors, including the Senior Achievement Award and the Leadership Development Program Award, both from the American Academy of Ophthalmology.
Financial disclosure: Dr. Ip has/had an affiliation (financial or otherwise) with a commercial organization:
1. Aerie
2. Allergan
3. Alimera
4. Amgen
5. Apellis
6. Cell Lineage Therapeutics
7. Clearside
8. Genentech
9. Novartis
10. OccuRX
11. Regeneron
12. RegenexBio
Sessions in which Michael Ip participates
- Long term changes in the choroid follwing PRP vs anti-VEGF treatment for proliferative diabetic retinopathy: An analysis from the DRCR Retina Network Protocol S dataset Halifax Convention Centre - C2
- Keynote speaker Michael Ip |
- 10:45 AM - 10:57 AM | 12 minutes Part of: Retina Surgical Advancements
- Keynote Speaker | Invité.e d'honneur
- Retina Surgical Advancements Halifax Convention Centre - C2
- 10:45 AM - 12:15 PM | 1 hour 30 minutes
- Learning ObjectivesAt the end of this session, participants will be able to:Assess and manage vitreoretinal...
- Talk | Exposé
- Correlation of the best corrected visual acuity and central subfoveal thickness due to retinal vein occlusion, diabetic retinopathy and uveitis: An analysis from randomized clinical trials Halifax Convention Centre - C2
- Keynote speaker Michael Ip |
- 1:30 PM - 1:42 PM | 12 minutes Part of: New Concepts in Medical and Surgical Retina
- Keynote Speaker | Invité.e d'honneur
- New Concepts in Medical and Surgical Retina Halifax Convention Centre - C2
- 1:30 PM - 3:00 PM | 1 hour 30 minutes
- Learning ObjectivesAt the end of this session, participants will be able to:Manage macular edema secondary t...
- Talk | Exposé
- Breaking News: Shaping the future of AMD and DME Halifax Convention Centre - C3
- 6:30 AM - 8:00 AM | 1 hour 30 minutes
- LEARNING OBJECTIVESAt the end of this symposium, participants will be able to:Identify the critical unmet ne...
- Co-Developed Symposium | Symposium élaboré conjointement
- New (non-surgical) treatments for nAMD and DME Halifax Convention Centre - C3
- Speaker Michael Ip |
- 6:40 AM - 6:52 AM | 12 minutes Part of: Breaking News: Shaping the future of AMD and DME
- Panel Discussion Halifax Convention Centre - C3
- Moderator Varun Chaudhary | Panelist Sunir J. Garg, MD, FACS, FASRS | Panelist Dr. Wai-Ching Lam | Panelist Michael Ip |
- 6:52 AM - 6:57 AM | 5 minutes Part of: Breaking News: Shaping the future of AMD and DME
- Panel | Table ronde
- Case presentation Halifax Convention Centre - C3
- Speaker Michael Ip |
- 7:07 AM - 7:10 AM | 3 minutes Part of: Breaking News: Shaping the future of AMD and DME
- Panel discussion Halifax Convention Centre - C3
- Panelist Michael Ip | Panelist Sunir J. Garg, MD, FACS, FASRS | Panelist Dr. Wai-Ching Lam | Moderator Varun Chaudhary |
- 7:10 AM - 7:25 AM | 15 minutes Part of: Breaking News: Shaping the future of AMD and DME
- Panel discussion Halifax Convention Centre - C3
- Panelist Dr. Wai-Ching Lam | Panelist Michael Ip | Panelist Sunir J. Garg, MD, FACS, FASRS | Moderator Varun Chaudhary |
- 7:40 AM - 7:50 AM | 10 minutes Part of: Breaking News: Shaping the future of AMD and DME
- Current Concepts III Halifax Convention Centre - C1
- 8:00 AM - 10:00 AM | 2 hours
- Learning ObjectivesAt the end of this session, participants will be able to:Recognize features of optic neur...
- Lecture | Conférence
- The top 5 findings from the SCORE2 Study Halifax Convention Centre - C1
- Keynote speaker Michael Ip |
- 8:12 AM - 8:22 AM | 10 minutes Part of: Current Concepts III
- Keynote Speaker | Invité.e d'honneur